Xvivo Perfusion (OM:XVIVO) has put fresh numbers on the table for Q2 2026, with revenue of SEK 239.0 million, basic EPS of SEK 0.52 and net income of SEK 16.3 million setting the tone for the latest update. The company has seen quarterly revenue move from SEK 178.3 million in Q2 2025 to SEK 238.99 million in Q2 2026, while basic EPS shifted from SEK 0.05 to SEK 0.52 and trailing twelve month EPS reached SEK 2.81. The key question for investors is whether current margins can justify the growth profile implied by these figures.

See our full analysis for Xvivo Perfusion.

With the latest results on the table, the next step is to set these hard numbers against the most common narratives around Xvivo Perfusion to see which views are supported and which are challenged by the recent margin and growth profile.

See what the community is saying about Xvivo Perfusion

Margins Softening Against Strong Growth Story

• Xvivo Perfusion's trailing net profit margin is 9.9%, compared with 13.5% a year ago, while trailing twelve month net income stands at SEK 88.6 million on SEK 895.2 million of revenue.
• Bulls point to strong forecasted earnings growth of 49.6% a year and revenue growth of 23.7% a year, yet the margin slip gives you a reality check against that optimism.
  • On the one hand, the bullish view highlights recurring consumables and scale benefits as drivers for higher margins over time, which aligns with the company being profitable over the last five years with 38.7% annual earnings growth.
  • On the other hand, the move from a 13.5% to 9.9% net margin shows that near term pressure from costs and investment can still bite, even when the long term growth narrative looks impressive on paper.

For investors who want to see how the bullish case connects these growth forecasts with future profitability, the full narrative breaks down the key assumptions in detail 🐂 Xvivo Perfusion Bull Case.

High P/E Valuation Versus Peers

• The stock trades on a P/E of 82.9x, well above both peer companies at 29.6x and the wider European Medical Equipment industry at 26.7x, while the current share price of SEK 233.00 sits below the DCF fair value of SEK 264.49.
• Skeptics focus on this rich P/E and recent margin compression, arguing that even with growth forecasts, Xvivo Perfusion is priced for a lot to go right.
  • Bears highlight that although the share price is about 11.9% below the DCF fair value and analysts point to a SEK 337.40 target, the combination of a high multiple and lower trailing margin limits room for disappointment.
  • They also point out that negative earnings growth over the most recent year contrasts with the strong five year trend, which they see as a warning that high expectations may be harder to sustain than the forecasts suggest.

Skeptical investors who want to stress test whether these concerns hold up under different scenarios can walk through the full cautious narrative 🐻 Xvivo Perfusion Bear Case.

Earnings Pattern Turning After Prior Volatility

• Quarterly net income has moved from a loss of SEK 12.4 million in Q1 2025 to profits of SEK 1.6 million in Q2 2025 and SEK 16.3 million in Q2 2026, with trailing twelve month EPS now at SEK 2.81.
• The balanced view notes that this earnings pattern, together with regulatory progress in markets like the U.S., Canada and Australia, creates a mixed but constructive backdrop rather than a one way story.
  • Consensus commentary links improving profitability versus early 2025 and the SEK 88.6 million trailing twelve month net income to expected benefits from approvals and higher margin segments such as the Abdominal business.
  • At the same time, it flags production capacity limits and regulatory timing as practical constraints, which helps explain why margins are still below last year's level despite healthier topline numbers.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xvivo Perfusion on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and cautious views on Xvivo Perfusion leaves you undecided, take a closer look at the figures and form your own stance using the detailed breakdown of 3 key rewards.

See What Else Is Out There

Xvivo Perfusion combines a high P/E, softer net margins and recent earnings volatility, which together leave little room for disappointment if expectations slip.

If that mix makes you cautious, compare it with companies highlighted in the 298 resilient stocks with low risk scores to quickly focus on steadier profiles that may better match your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.